The focus of the Device Technologies stand was the new Myah system from Topcon, a management tool for eyecare professionals interested in building, managing and growing their myopia and dry eye services.
Medmont has launched its next generation Meridia Advanced Topographer, raising the bar on high-performance corneal topography combined with dry eye evaluation all in one, said the company.
Oyster Point Pharma has submitted an application to the US Food and Drug Administration (FDA) for its OC-01 (varenicline) nasal spray for the treatment of signs and symptoms
High prevalence of abnormal ocular surface tests in a healthy paediatric population
Associate Professor Jennifer Craig, head of the Ocular Surface Laboratory (OSL) at the University of Auckland and a leading, international dry eye researcher, has been made a
New Zealand optometrist and contact lens specialist Jagrut Lallu has developed a new cloud-based dry eye tool to help advance research and support clinician’s dry eye treatment assessments and patient management.
Hollywood actress Jennifer Aniston suffers from dry eye disease, admitting she was “addicted to eye drops” and has trouble reading scripts due to dry, itchy eyes, in an interview with Health magazine.
Newly unveiled in Australasia, Device Technologies’ Topcon Myah is a management tool designed for eye care professionals looking to build, manage and grow myopia and dry eye services within their practice.
Clinicians and patients are faced with an overwhelming choice of artificial tear supplements as a therapy for their dry eye disease (DED). Focus was once on the lacrimal gland and aqueous tear deficiency, however meibomian gland dysfunction and tear film lipid deficiency are increasingly recognised
The modern workplace serves as a catalyst for dry eye disease (DED) and ocular discomfort for many. Air conditioning, central heating and extended digital screen use promote accelerated tear film evaporation and instability. Previous Ocular Surface Laboratory (OSL) research has demonstrated prophyla
Dry eye disease (DED) affects approximately one in three New Zealanders. As clinicians, it’s critical that we accurately diagnose and manage this impactful disease. Left untreated, DED is detrimental to patients’ quality of life with its impact ranging from intermittent ocular discomfort to more ser
